{
  "docId": "019de076-5055-7033-9b06-edc885bd7bb4",
  "docSlug": "654baeecef2359d21ce8a7c6619fff57",
  "documentTitle": "Legend Biotech | Results Presentation Deck | 15 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 15,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "other",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide outlines a deal structure involving upfront payments, milestones, royalties, and a division of development labor.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-5055-7033-9b06-edc885bd7bb4/6",
  "deckHref": "/decks/019de076-5055-7033-9b06-edc885bd7bb4",
  "deckJsonHref": "/decks/019de076-5055-7033-9b06-edc885bd7bb4.json",
  "deckAnchorHref": "/decks/019de076-5055-7033-9b06-edc885bd7bb4#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.52,
        "y": 0.7
      },
      "kind": "list",
      "text": "Legend to conduct Ph1 for LB2102 in the US\nNovartis to conduct all other development for the licensed products",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29d812f7-9d5f-48a4-89e5-850561e53c57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.7,
        "y": 0.4
      },
      "kind": "list",
      "text": "Tiered Royalties on Net Sales",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef1b991b-f02b-4a88-820e-5eb5d024aad6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.13,
        "y": 0.4
      },
      "kind": "metric",
      "text": "$100M",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f5254e5-4628-4a01-8360-efa9a4d2a2a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.43,
        "y": 0.4
      },
      "kind": "metric",
      "text": "$1.01B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5cfb7c2-05ce-41ec-a7c5-953212f21ef2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.105,
        "y": 0.2
      },
      "kind": "subtitle",
      "text": "Legend announced on Nov 13, 2023 an exclusive, global license agreement with Novartis to advance certain DLL3-targeted CAR-T therapies, including LB2102, an investigational therapy for small cell lung cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3369b30a-c334-45b3-b22e-008cdc221503",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.105,
        "y": 0.05
      },
      "kind": "title",
      "text": "Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00317c9d-cee1-4ba8-9237-63b5a1047a9c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 5,
      "beatId": "fe1e4644-f867-426f-980d-baf06152e447",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The KPI overview and financial highlights slides demonstrate the company's performance",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 6,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "8f8f6984-d7d1-4755-98e2-7a2a35e26a2b",
      "evidence": "The out-licensing deal slide presents a specific example of the company's strategy",
      "position": 1,
      "objective": "Out-licensing deal as a strategic move",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.5,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}